Skip to content

Ketamine for suicidal ideations in severe depression

Rakesh Garg, Gurmeet Kaur Brar, Manpreet K. Singh

Adesh University Journal of Medical Sciences & Research September 25, 2025 DOI: 10.25259/aujmsr_65_2025 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case report Peer reviewed
Sample size 1
Population 38-year-old female with recurrent depressive disorder and active suicidal ideation
Intervention Ketamine infusion
Topics Depression Ketamine Esketamine
Keywords Tolerability Antidepressant Depression economics Blockade Rating scale Depressive symptoms Suicidal ideation Anesthesia Nmda receptor Glutamatergic Mechanism biology Genetic neurodegenerative diseases
Key findings A single ketamine infusion reduced HDRS score from 33 to 23 and decreased suicidal ideation in a patient with treatment-resistant depression.

Abstract

This case report describes the management of a 38-year-old female with recurrent depressive disorder, who presented with severe depressive symptoms and active suicidal ideations. She reported persistent low mood, loss of interest in pleasurable activities, fatigue, and disturbed sleep for nearly three weeks, with recurrent thoughts of ending her life in the preceding week. Despite being on multiple psychotropic medications including lamotrigine, desvenlafaxine, mirtazapine, and benzodiazepines, her symptoms had worsened, warranting urgent intervention. On admission, her Hamilton Depression Rating Scale (HDRS) score was 33, indicating severe depression. In view of high suicidal risk and inadequate response to ongoing treatment, ketamine infusion was planned as a rapid-acting antidepressant strategy. Following the first session, her HDRS score reduced to 23, accompanied by a noticeable decline in suicidal ideations. This improvement highlights the potential of ketamine as a fast-acting therapeutic option in cases of severe depression with suicidality. Acting through NMDA receptor blockade and modulation of glutamatergic transmission, ketamine offers a novel mechanism distinct from conventional antidepressants. The case supports the growing evidence base for the use of ketamine in psychiatric emergencies where rapid symptom relief is critical and underscores its tolerability at sub-anesthetic doses.

Comparable studies

Other case reports and case series on ketamine for depression, most cited first.

Study Year Design Participants
Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. A patient with treatment-resistant depression and comorbid generalized anxiety... 2025 Case report n = 1
A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression Patients with enduring eating disorders and treatment-resistant depression 2021 Case series n = 4
Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series Veterans with co-morbid depression and PTSD 2022 Retrospective case series n = 35
Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa Patients with anorexia nervosa and a comorbid depressive disorder treated at a private... 2023 Case report n = 4
Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder Patients with treatment-resistant depression and comorbid PTSD 2023 Case series n = 5

Explore topics

By condition and practice